PubRank

George R Uhl

Author PubWeight™ 118.86‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med 2008 2.91
2 Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006 2.62
3 Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res 2005 2.34
4 Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet B Neuropsychiatr Genet 2006 2.09
5 Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006 2.07
6 Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc Natl Acad Sci U S A 2005 2.00
7 Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes. Am J Med Genet B Neuropsychiatr Genet 2006 1.95
8 Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol Med 2010 1.83
9 Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst 2012 1.83
10 Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet 2005 1.60
11 Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Hum Mol Genet 2007 1.56
12 Linkage disequilibrium, haplotype and association studies of a chromosome 4 GABA receptor gene cluster: candidate gene variants for addictions. Am J Med Genet B Neuropsychiatr Genet 2006 1.51
13 Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology 2003 1.48
14 Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities. Pharmacogenomics J 2003 1.42
15 Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 2004 1.41
16 Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J Neurosci 2009 1.33
17 A human-specific de novo protein-coding gene associated with human brain functions. PLoS Comput Biol 2010 1.31
18 CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res 2011 1.31
19 Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. Mol Med 2008 1.27
20 Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008 1.26
21 NrCAM in addiction vulnerability: positional cloning, drug-regulation, haplotype-specific expression, and altered drug reward in knockout mice. Neuropsychopharmacology 2006 1.24
22 Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 2008 1.23
23 How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 2005 1.22
24 Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 2004 1.15
25 Genome wide association for substance dependence: convergent results from epidemiologic and research volunteer samples. BMC Med Genet 2008 1.12
26 Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 2008 1.12
27 Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology 2006 1.09
28 SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 2005 1.08
29 Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain 2013 1.06
30 Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 2006 1.05
31 Genome wide association for addiction: replicated results and comparisons of two analytic approaches. PLoS One 2010 1.04
32 Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Mol Med 2009 1.02
33 Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 2006 1.01
34 OKCAM: an ontology-based, human-centered knowledgebase for cell adhesion molecules. Nucleic Acids Res 2008 1.01
35 Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci 2004 1.00
36 Genomic regions identified by overlapping clusters of nominally-positive SNPs from genome-wide studies of alcohol and illegal substance dependence. PLoS One 2011 1.00
37 Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 2003 1.00
38 mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res Mol Brain Res 2004 1.00
39 Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol 2007 1.00
40 Convergent genome wide association results for bipolar disorder and substance dependence. Am J Med Genet B Neuropsychiatr Genet 2009 0.99
41 Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. Int J Neuropsychopharmacol 2012 0.99
42 Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol 2002 0.98
43 Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression. Methods Mol Med 2006 0.97
44 KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine. J Biol Chem 2002 0.96
45 Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002 0.95
46 Supplementing high-density SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS One 2009 0.94
47 The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem Pharmacol 2005 0.94
48 Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacol Ther 2013 0.93
49 dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice. Eur J Pharmacol 2006 0.93
50 Reduced emotional and corticosterone responses to stress in mu-opioid receptor knockout mice. Neuropharmacology 2009 0.92
51 Meta-analysis and genome-wide interpretation of genetic susceptibility to drug addiction. BMC Genomics 2011 0.91
52 Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. Biol Psychiatry 2007 0.91
53 Impaired spatial working memory and decreased frontal cortex BDNF protein level in dopamine transporter knockout mice. Eur J Pharmacol 2009 0.91
54 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav 2009 0.90
55 Deletion of v7-3 (SLC6A15) transporter allows assessment of its roles in synaptosomal proline uptake, leucine uptake and behaviors. Brain Res 2007 0.90
56 Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 2007 0.90
57 "Replicated" genome wide association for dependence on illegal substances: genomic regions identified by overlapping clusters of nominally positive SNPs. Am J Med Genet B Neuropsychiatr Genet 2010 0.89
58 Impaired cliff avoidance reaction in dopamine transporter knockout mice. Psychopharmacology (Berl) 2013 0.89
59 Mouse brain gene expression changes after acute and chronic amphetamine. J Neurochem 2003 0.89
60 Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5'UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer's disease. Subst Use Misuse 2010 0.88
61 Food-reinforced operant behavior in dopamine transporter knockout mice: enhanced resistance to extinction. Ann N Y Acad Sci 2004 0.88
62 GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. Biochem J 2004 0.87
63 Intracisternal A-particle element in the 3' noncoding region of the mu-opioid receptor gene in CXBK mice: a new genetic mechanism underlying differences in opioid sensitivity. Pharmacogenet Genomics 2006 0.87
64 Decreased response to social defeat stress in μ-opioid-receptor knockout mice. Pharmacol Biochem Behav 2011 0.87
65 Altered neurocircuitry in the dopamine transporter knockout mouse brain. PLoS One 2010 0.86
66 Dopamine, norepinephrine and serotonin transporter gene deletions differentially alter cocaine-induced taste aversion. Pharmacol Biochem Behav 2009 0.86
67 Setting priorities for genomic research. Science 2004 0.86
68 Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. Brain Res 2006 0.85
69 Effects of acute "binge" cocaine on preprodynorphin, preproenkephalin, proopiomelanocortin, and corticotropin-releasing hormone receptor mRNA levels in the striatum and hypothalamic-pituitary-adrenal axis of mu-opioid receptor knockout mice. Synapse 2002 0.85
70 The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse. Pharmacogenetics 2004 0.84
71 Quantitative pharmacologic MRI: mapping the cerebral blood volume response to cocaine in dopamine transporter knockout mice. Neuroimage 2010 0.84
72 Increased body weight in mice lacking mu-opioid receptors. Neuroreport 2006 0.84
73 Behavioral methods in cannabinoid research. Methods Mol Med 2006 0.84
74 Sex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans. Nicotine Tob Res 2010 0.83
75 An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice. Psychopharmacology (Berl) 2013 0.83
76 Dopamine uptake and cocaine binding mechanisms: the involvement of charged amino acids from the transmembrane domains of the human dopamine transporter. Eur J Pharmacol 2006 0.82
77 Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 gene. J Pharmacol Sci 2003 0.82
78 Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine. Psychopharmacology (Berl) 2011 0.81
79 Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal. Synapse 2008 0.81
80 Dopamine efflux via wild-type and mutant dopamine transporters: alanine substitution for proline-572 enhances efflux and reduces dependence on extracellular dopamine, sodium and chloride concentrations. Brain Res Mol Brain Res 2002 0.81
81 Antidepressant-like effect of venlafaxine is abolished in μ-opioid receptor-knockout mice. J Pharmacol Sci 2010 0.81
82 Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochem Int 2007 0.81
83 Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice. Neuropsychopharmacology 2012 0.81
84 Agmatine attenuates methamphetamine-induced hyperlocomotion and stereotyped behavior in mice. Behav Pharmacol 2014 0.80
85 Involvement of the neutral amino acid transporter SLC6A15 and leucine in obesity-related phenotypes. PLoS One 2013 0.80
86 NrCAM-regulating neural systems and addiction-related behaviors. Addict Biol 2012 0.80
87 Variation in a bicarbonate co-transporter gene family member SLC4A7 is associated with propensity to addictions: a study using fine-mapping and three samples. Addiction 2007 0.80
88 B(0)AT2 (SLC6A15) is localized to neurons and astrocytes, and is involved in mediating the effect of leucine in the brain. PLoS One 2013 0.80
89 Isolation and sequencing of a putative promoter region of the murine G protein beta 1 subunit (GNB1) gene. DNA Seq 2002 0.79
90 Association of PTPRB gene polymorphism with drug addiction. Am J Med Genet B Neuropsychiatr Genet 2008 0.79
91 Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. JAMA 2002 0.78
92 Families of protein phosphatase 1 modulators activated by protein kinases a and C: focus on brain. Prog Nucleic Acid Res Mol Biol 2005 0.78
93 (-)-Pentazocine induces visceral chemical antinociception, but not thermal, mechanical, or somatic chemical antinociception, in μ-opioid receptor knockout mice. Mol Pain 2011 0.78
94 Altered reward circuitry in the norepinephrine transporter knockout mouse. PLoS One 2013 0.78
95 Comparative inter-strain sequence analysis of the putative regulatory region of murine psychostimulant-regulated gene GNB1 (G protein beta 1 subunit gene). DNA Seq 2003 0.78
96 Regulation of dopamine and MPP+ transport by catecholamine transporters. Nihon Shinkei Seishin Yakurigaku Zasshi 2004 0.78
97 Attenuated methamphetamine-induced locomotor sensitization in serotonin transporter knockout mice is restored by serotonin 1B receptor antagonist treatment. Behav Pharmacol 2015 0.78
98 Mouse models for studying genetic influences on factors determining smoking cessation success in humans. Ann N Y Acad Sci 2012 0.77
99 Exclusive expression of VMAT2 in noradrenergic neurons increases viability of homozygous VMAT2 knockout mice. Biochem Biophys Res Commun 2013 0.77
100 Reducing aggression and impulsivity through school-based prevention programs: a gene by intervention interaction. Prev Sci 2014 0.77
101 Knocking out the dopamine reuptake transporter (DAT) does not change the baseline brain arachidonic acid signal in the mouse. Int J Neurosci 2012 0.77
102 Dietary restriction mitigates cocaine-induced alterations of olfactory bulb cellular plasticity and gene expression, and behavior. J Neurochem 2010 0.77
103 Quantitative Detection of µ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice. Curr Neuropharmacol 2011 0.77
104 Promise of pharmacogenomics in smoking cessation. Pharmacogenomics 2009 0.77
105 The μ opioid receptor is not involved in ethanol-stimulated dopamine release in the ventral striatum of C57BL/6J mice. Alcohol Clin Exp Res 2011 0.77
106 Developmental alterations in anxiety and cognitive behavior in serotonin transporter mutant mice. Psychopharmacology (Berl) 2014 0.76
107 Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine. Neuropharmacology 2012 0.76
108 Histamine H3 receptor agonists decrease hypothalamic histamine levels and increase stereotypical biting in mice challenged with methamphetamine. Neurochem Res 2011 0.76
109 mu-Opioid receptor-independent fashion of the suppression of sodium currents by mu-opioid analgesics in thalamic neurons. Neurosci Lett 2009 0.76
110 The selective μ opioid receptor antagonist β-funaltrexamine attenuates methamphetamine-induced stereotypical biting in mice. Brain Res 2013 0.76
111 Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in mu-opioid receptor knockout mice. Neuropharmacology 2008 0.76
112 Proline mutations induce negative-dosage effects on uptake velocity of the dopamine transporter. J Neurochem 2005 0.76
113 Specific regions display altered grey matter volume in μ-opioid receptor knockout mice: MRI voxel-based morphometry. Br J Pharmacol 2014 0.75
114 Straub tail reaction in mice treated with σ(1) receptor antagonist in combination with methamphetamine. Brain Res 2012 0.75
115 A single administration of methamphetamine to mice early in the light period decreases running wheel activity observed during the dark period. Brain Res 2011 0.75
116 Methylone-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Behav Pharmacol 2015 0.75
117 Introduction to Addiction Reviews 2. Ann N Y Acad Sci 2010 0.75
118 Needed: mouse/human cross validation of reinstatement/relapse models (and drug reward models) to model human substance abuse vulnerability allelic variants. Psychopharmacology (Berl) 2003 0.75
119 Sex differences in the effects of adolescent social deprivation on alcohol consumption in μ-opioid receptor knockout mice. Psychopharmacology (Berl) 2014 0.75